Chinese Court Orders Kangmei Pharmaceutical Founders to Pay Nearly 1.4 Billion Yuan

Chinese judicial authorities have targeted the primary instigators of the Kangmei Pharmaceutical financial fraud, ordering founder Ma Xingtian and his wife to pay nearly 1.4 billion yuan in compensation. The ruling reflects a broader judicial and regulatory push in China toward zero tolerance for capital market violations, specifically focusing on personal financial liability for controlling shareholders who orchestrate corporate misrepresentation.

The Kangmei Pharmaceutical case stands as one of the most severe accounting fraud scandals in the history of China's A-share market. Directly seeking nearly 1.4 billion yuan in compensation from the primary culprits reflects a commitment by regulatory and judicial authorities to enforce zero tolerance and precisely hold accountable the key individuals driving corporate misconduct.

In a major development concerning one of China's most notorious corporate accounting scandals, former Kangmei Pharmaceutical founder Ma Xingtian and his wife have been ordered to pay nearly 1.4 billion yuan (approximately $190 million) in compensation. The ruling targets the key perpetrators responsible for massive financial fabrications at the listed pharmaceutical company. The Kangmei Pharmaceutical fraud case represents a watershed moment in the enforcement of capital market regulations in China's A-share market. Over several years, the company engaged in extensive accounting manipulations, falsifying cash balances and financial statements on an unprecedented scale. The decision to hold controlling shareholders personally liable for nearly 1.4 billion yuan highlights a deliberate strategy by Chinese judicial and regulatory authorities to enforce a strict policy against financial misrepresentation. Rather than relying solely on corporate penalties that often indirectly burden minority shareholders, judicial authorities are increasingly focusing accountability on key controllers—specifically controlling shareholders, actual controllers, and senior management who directly orchestrate corporate misdeeds. By pursuing personal financial judgments of this magnitude, legal authorities aim to create a strong deterrent against future corporate fraud and protect investor rights. This action aligns with broader institutional reforms in China's financial legal system aimed at strengthening civil compensation mechanisms and refining civil litigation processes for securities disputes. In recent years, regulatory bodies such as the China Securities Regulatory Commission and the judiciary have introduced mechanisms to streamline class-action-style civil lawsuits and hold third-party intermediaries, such as auditing firms and financial advisors, liable alongside corporate executives. Moving forward, market participants will closely watch the execution phase of the court order, particularly how frozen assets and personal holdings will be liquidated to satisfy the compensation judgment. Observers are also monitoring potential follow-up enforcement actions targeting other responsible entities and intermediaries connected to the Kangmei fraud, which could set further legal precedents for corporate governance and investor protection in China.